Navigation Links
Hana Biosciences Announces New Positive Interim Efficacy Results in Pivotal rALLy Clinical Trial of Marqibo in Acute Lymphoblastic Leukemia
Date:3/3/2009

- 31% COMPLETE RESPONSE RATE

- MEDIAN SURVIVAL OF 10.5 MONTHS IN COMPLETE RESPONDERS

- FINAL DATA TARGETED FOR 2009 ASH ANNUAL MEETING

SOUTH SAN FRANCISCO, Calif., March 3 /PRNewswire-FirstCall/ -- Hana Biosciences (Nasdaq: HNAB) today announced new positive preliminary efficacy results from a planned interim analysis of the ongoing pivotal rALLy clinical trial evaluating Marqibo(R) (vincristine sulfate liposomes injection) for the treatment of adult acute lymphoblastic leukemia (ALL) in second relapse. The analysis revealed that nine patients, or 31 percent, of the first 29 evaluable subjects achieved a complete response (CR) or CR without full blood count recovery (CRi). The estimated median overall survival (OS) in responders was 10.5 months compared to 5.1 months in non-responders at the time of the data cutoff. Because six of the nine CRs were still alive at that time, the median OS in this group may prove to be longer.

Since the outset of the rALLy trial, the target response rate for the study has been 16% complete responses (i.e., CR or CRi), which equates to nine or more out of the target evaluable population of 56 subjects. Completion of rALLy will satisfy the Company's need for greater than 100 Marqibo-treated adult ALL patients and catalyze the completion and submission of a New Drug Application for accelerated approval.

"We are strongly encouraged by these excellent preliminary results that show we have already met our overall study goal with regards to the number of complete responses in the first 29 patients, and importantly corroborate previously reported Marqibo activity in past clinical trials," said Steven R. Deitcher, M.D., president and chief executive officer. "These data fully support our plans to submit a New Drug Application for accelerated approval of
'/>"/>

SOURCE Hana Biosciences
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Hana Biosciences Announces Successful Planned Independent Safety Analysis Supports Ability to Complete Pivotal rALLy Clinical Trial of Marqibo, Its Lead Novel Anti-Cancer Compound
2. Cardio3 BioSciences Raises EUR13.7 Million in Series B Fundraising and Grant Funding
3. YM BioSciences Announces Milestone Payment For Approval Of Nimotuzumab In The Philippines And Indonesia
4. Sangamo BioSciences Provides Update on Companys 2008 Progress and 2009 Objectives
5. Chipscreen Biosciences and HUYA Bioscience Intl Announce Promising Preclincial and Phase I Solid Tumor/Lymphoma Data for Chidamide/HBI-8000, New HDAC Inhibitor for Cancer
6. Regado Biosciences Completes Patient Enrollment for Phase IIa Study of REG1 Anticoagulation System
7. Ardea Biosciences Presents Preclinical Anti-Inflammatory Data on its Lead MEK Inhibitor, RDEA119, at the ACG 2008 Annual Meeting
8. Epiphany Biosciences to Continue Phase 2 Shingles Study After Interim Analysis; Plans Follow-On Clinical Trial Studying Post-Herpetic Neuralgia (PHN)
9. Ardea Biosciences to Present Data on Lead MEK Inhibitor, RDEA119, at American College of Gastroenterology Annual Scientific Meeting
10. Sangamo BioSciences Initiates Phase 2 Clinical Trial of Treatment for Amyotrophic Lateral Sclerosis (ALS)
11. Neurocrine Biosciences Announces Successful Elagolix PETAL Study in Endometriosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)...  In today,s ever-changing marketplace, call centers must meet ... connected, and increasingly impatient with slow service. The need ... and tools is driving call centers to explore new ... According to research by benchmarking firm, Best Practices, LLC, ... a call center study realize the impact of social ...
(Date:7/31/2015)... -- More than 1,500 substance abuse prevention and treatment ... Indianapolis Aug. 2-6 for Community Anti-Drug ... . The week-long training, held at the JW Marriott, ... nation,s biggest public health challenges – youth drug use. ... one-of-a-kind intensive training opportunity, offering more than 70 half-day ...
(Date:7/31/2015)... 2015 RnRMarketResearch.com adds Syringes ... report that provides an overview of syringes and ... from in-house databases, secondary and primary research. ... products pipeline spread across 124 pages, talking about ... and 5 figures is now available at ...
Breaking Medicine Technology:Best Practices in Building World-Class Consumer & Over-the-Counter Call Centers 2Community Leaders From Across The Country Head To Indianapolis For CADCA 2015 Mid-Year Training Institute Aug. 2-6 2Syringes and Needles Market Products Pipeline Review 2015 Report 2Syringes and Needles Market Products Pipeline Review 2015 Report 3Syringes and Needles Market Products Pipeline Review 2015 Report 4Syringes and Needles Market Products Pipeline Review 2015 Report 5
... The introduction of Invivo Corporation,s DynaCAD for Prostate ... hope to patients and new confidence to their care ... , A five-year collaborative effort with Fox Chase Cancer ... of Chicago, IL; and Desert Medical Imaging, CA resulted ...
... LAKE FOREST, Ill., Sept. 30 Hospira, Inc. (NYSE: ... delivery company, today announced the acquisition of worldwide rights ... European manufacturing facility from PLIVA Hrvatska d.o.o. (Zagreb, Croatia) ... reach and vertical integration in biogenerics. Financial terms ...
Cached Medicine Technology:Urologists, Radiologists, Patients Benefit From New Clinical Prostate Visualization System 2Hospira Acquires Worldwide Rights to Biogeneric Version of Filgrastim and Manufacturing Facility From PLIVA 2Hospira Acquires Worldwide Rights to Biogeneric Version of Filgrastim and Manufacturing Facility From PLIVA 3
(Date:8/1/2015)... New York, NY (PRWEB) , ... August 01, 2015 , ... ... Black Vine cyberespionage group , who are thought to have been behind the attack ... Among the topics covered were zero day exploits, watering hole attacks and spear phishing ...
(Date:7/31/2015)... ... July 31, 2015 , ... That’s ... What are the STASH awards? The Significant Technological Achievements in Secretive Horticulture (or ... as well as tried-and-true products that have stood the test of time. These ...
(Date:7/31/2015)... , ... July 31, 2015 , ... Ticket Down is ... currently going on in Chicago at Grant Park. The festival will end on ... North America to Chicago for the annual Lollapalooza. This unique and unbelievably popular ...
(Date:7/31/2015)... ... , ... Sculpted Contours Luxury Medical Aesthetics announces the arrival of the newest ... this new applicator in the United States as an upgrade to the CoolSmooth applicator ... original applicator required a 2 hour treatment time. The new CoolSmooth Pro reduces ...
(Date:7/31/2015)... ... July 31, 2015 , ... M3 USA MDLinx.com, source of ... three new Board Exam Courses. , The additions of Gastroenterology, Pulmonology and Allergy/Immunology ... from MDLinx makes preparing for the exam easy and painless. MDLinx offers thousands ...
Breaking Medicine News(10 mins):Health News:Frenemy at the Gates - Hackers Excel at Leveraging Trust 2Health News:Frenemy at the Gates - Hackers Excel at Leveraging Trust 3Health News:Frenemy at the Gates - Hackers Excel at Leveraging Trust 4Health News:The High Times S.T.A.S.H. Awards Are in, Guess Who Took Home the Prize for “Best Grow System” 2Health News:Cheap 2015 Lollapalooza Tickets: Ticket Down Slashes Ticket Prices on Lollapalooza Tickets at Grant Park in Chicago for Saturday, August 1st and Sunday, August 2nd 2Health News:Cooler Coolsculpting in Atlanta: Treatments Now Twice As Fast 2Health News:Cooler Coolsculpting in Atlanta: Treatments Now Twice As Fast 3Health News:MDLinx Offers Three New Board Exam Prep Courses - Gastroenterology, Pulmonology and Allergy/Immunology 2Health News:MDLinx Offers Three New Board Exam Prep Courses - Gastroenterology, Pulmonology and Allergy/Immunology 3
... Recent ... skin shrinkage of up to 40% one month post-procedure, allowing patients lose up to ... ... Recent studies conducted by leading plastic surgeon Dr. Mokhtar Asaadi reveal that patients undergoing ...
... ... technology development company, unveiled it,s HyperSign product at the Digital Signage Expo in March, ... digital signage solution. The software-as-a-service (SaaS) product simply and seamlessly delivers HD-quality content ... other similar products. , ...
... translation programs give confusing, incomplete instructions, study finds ... Spanish-speaking people in the United States receive prescription ... the medications are potentially hazardous to their health, ... largely because of deficiencies in computer programs that ...
... ... , ... April 8, 2010 -- Centegra Health System is proud to announce McHenry ... for women’s breast care needs, thanks to a $500,000 donation from the Gavers Community ...
... over many years, study suggests , THURSDAY, April 8 (HealthDay ... apnea more than doubles the risk for stroke in men ... , U.S. researchers looked at more than 5,400 people, age ... were participating in the Sleep Heart Health Study. The participants ...
... found a chemical compound that, when used in conjunction ... by antibiotic-resistant strains of bacteria such as the ... compound also re-sentsitizes those bacteria to antibiotics. Infections ... to get rid of because the bacteria can attach ...
Cached Medicine News:Health News:Recent Studies Show MAstertuck℠ Technique Removes Large Amounts of Body Fat without Tummy Tuck Surgery 2Health News:Recent Studies Show MAstertuck℠ Technique Removes Large Amounts of Body Fat without Tummy Tuck Surgery 3Health News:Recent Studies Show MAstertuck℠ Technique Removes Large Amounts of Body Fat without Tummy Tuck Surgery 4Health News:rAVe Publications Awards HyperSign "Most Innovative New Digital Signage Solution" 2Health News:Prescriptions Translated to Spanish Could Be Hazardous to Health 2Health News:Prescriptions Translated to Spanish Could Be Hazardous to Health 3Health News:Centegra Gavers Breast Center to Open in Crystal Lake 2Health News:Centegra Gavers Breast Center to Open in Crystal Lake 3Health News:Centegra Gavers Breast Center to Open in Crystal Lake 4Health News:Even Mild Sleep Apnea Raises Stroke Risk in Men 2Health News:Researchers find compound effective in destroying antibiotic-resistant biofilms 2
For regulating sample flow rate when using the QIAvac 24 Plus;...
Holder for QIAGEN 96-well plates, for use with QIAvac 96;...
For connecting the QIAvac 24 Plus and Vacuum Pump;...
For monitoring vacuum pressure, suitable for use with all QIAvac manifolds;...
Medicine Products: